Results 151 to 160 of about 26,340 (266)

AS1842856 Reduces β‐Amyloid Burden via Inhibiting PLA2G4A‐Mediated Lysosomal Dysfunction in APP/PS1 Mice

CNS Neuroscience &Therapeutics, Volume 32, Issue 4, April 2026.
AS1842856 reduces intracellular levels of GSK3α/β by binding to them and promoting their exocytosis. This reduction leads to diminished GSK3β‐mediated activation of NF‐κB, resulting in decreased transcription of PLA2G4A and reduced lysosomal damage. Ultimately, this enhances lysosomal degradation of Aβ, lowering Aβ load in APP/PS1 mice.
Da‐Long He, Zheng Wu, Rong‐Jun Jia, Ting‐Yao Wu, Yi‐Min Qiu, Yong‐Gang Fan   +5 more
wiley   +1 more source

Neprilysin [PDF]

, 2020
openaire   +1 more source

Predictors and Outcomes of Pharmacological and Electrical Cardioversion for Atrial Fibrillation and Flutter in an Indian Emergency Department: A Retrospective Study

Journal of Arrhythmia, Volume 42, Issue 2, April 2026.
In a real‐world emergency department study of atrial fibrillation and flutter, cardioversion restored sinus rhythm in 68% of patients. Electrical cardioversion achieved the highest success, while pharmacological and mixed strategies predicted failure. Complications were infrequent but clinically significant.
Abid M. Sadiq, Bhavana Keerthiparti, Kapil Kumawat, Deepak Padmanabhan   +3 more
wiley   +1 more source

Angiotensin Receptor-Neprilysin Inhibition.

Journal of cardiovascular pharmacology and therapeutics, 2018
The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while ...
Ofer, Havakuk, Uri, Elkayam
openaire   +1 more source

Current Status of Implantable Cardioverter‐Defibrillators (ICDs)/Cardiac Resynchronization Therapy With Defibrillators (CRT‐Ds) for Primary Prevention of Sudden Cardiac Death

Journal of Arrhythmia, Volume 42, Issue 2, April 2026.
Among recipients of ICDs/CRT‐Ds, the proportion of non‐ischemic cardiomyopathy is more than 60% in Japan. Despite recent concerns about primary prevention ICD/CRT‐D implantation for non‐ischemic patients with HFrEF in guideline‐directed medical therapy, ICD/CRT‐D therapy is likely effective in reducing the slope of the relationship between all‐cause ...
Hisashi Yokoshiki, Masaya Watanabe, Takeshi Mitsuhashi, Akihiko Shimizu   +3 more
wiley   +1 more source

Sacubitril/Valsartan Ameliorates Inflammation and Oxidative Stress in Hypertensive Heart Disease by Upregulating CAMKK2 Protein and Modulating the AMPK/AKT/GSK‐3β Axis

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 4, April 2026.
ABSTRACT Sacubitril/valsartan (Sac/Val) has emerged as an effective compound with myocardium‐protective functions in experimental and clinical trials for heart failure. This study investigated the function of Sac/Val in hypertensive heart disease (HHD) and explored the underlying mechanism.
Yan‐Jun Yang, Jiu‐Sheng Li
wiley   +1 more source

Antihypertensive medications and risk of Alzheimer's disease: Evidence for specific medication use

Alzheimer's &Dementia: Translational Research &Clinical Interventions, Volume 12, Issue 2, April/June 2026.
Abstract BACKGROUND Hypertension is a modifiable risk factor for Alzheimer's disease (AD). Specific antihypertensive classes may lower/increase AD risk by affecting the renin–angiotensin–aldosterone system. METHODS We investigated AD risk in relation to antihypertensive medications in a population‐based study of 33,714 incident AD cases and 897,872 ...
Osvaldo J. Laurido‐Soto, Alejandra Camacho‐Soto, Irene M. Faust, Kassu M. Beyene, Aaron J. Katz, Jordan A. Killion, Brad A. Racette   +6 more
wiley   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

Comparative effectiveness of pharmacotherapy for heart failure with preserved ejection fraction: A systematic review and network meta‐analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3137-3145, April 2026.
Abstract Aim Heart failure with preserved ejection fraction (HFpEF) presents a therapeutic challenge, characterised by a paucity of validated treatments. Emerging data suggest that targeting adiposity is central to HFpEF pathogenesis. We conducted an updated network meta‐analysis to compare the efficacy of emerging and established HFpEF therapies ...
Szu‐Han Chen, Yu‐Wen Tseng, Chi‐Jung Huang, Shu‐Mei Yang, Marat Fudim, Shao‐Yuan Chuang, Shih‐Hsien Sung, Hao‐Min Cheng   +7 more
wiley   +1 more source

Added Value of Rotational Mechanics to Longitudinal Indices in the Risk Stratification of Patients With Left Ventricular Hypertrophy

Echocardiography, Volume 43, Issue 4, April 2026.
The present study shows how 2D‐speckle tracking echocardiographic measures of myocardial rotational mechanics provide valuable information about the LVEF spectrum in patients with left ventricular hypertrophy. The primary outcome of interest is that rotational gradient (RG) is closely linked to global longitudinal strain (GLS).
Juan Geraldo, Celia Gil, Alejandro Queipo, Guillermo García‐Martín, Ester Galiana, Alberto Hidalgo, Paula Gramage, Hector Martinez‐Navarro, Jorge Lowenstein, Ildefonso Roldán, Vicente Mora   +10 more
wiley   +1 more source